Therapeutic Developability Analysis

Evaluating the developability of therapeutic drug candidates early can help circumvent potential issues in late-stage development. These evaluations include the drug candidate’s biophysical and chemical properties assessment. At Curia, in silico predictive tools and a series of fast & small-scale assessments are employed to serve as additional selection criteria for better and safe therapeutic leads.

Curia offers three developability assessment packages:

Developability Package 1	Developability Package 2	Developability Package 3
– In silico sequence liability analysis – In silico immunogenicity analysis – Turnaround time: 1 week	– Polyspecificity assessment – Integrity and stability assessment – Turnaround time: 2-3 weeks	– Buffer exchange – Forced degradation – Integrity and stability assessment – Additional stress conditions

Key Highlights

In silico Analysis: Application of Bioinformatic Tools

• Heavy and light chain variable region liability analysis
• VH and VL analysis with identification of core residues with potential affinity to MHC class II

Rapid Integrity Assessments and Formulation Studies for Drug Candidates

• Polyspecificity and integrity assessment can be completed in 2-3 weeks
• Formulation studies can be completed in 5 – 6 weeks, including the standard 2 weeks of incubation for accelerated stress conditions

Robust Bioanalytical Assays and Formulation Studies with Minimal Materials Required

• The standard panel includes common formulations used for commercial antibodies
• Various bioanalytical assays and characterization tools are provided
• A small amount of materials are needed for the bioanalytical assays and formulation studies.